Unique ID issued by UMIN | UMIN000026340 |
---|---|
Receipt number | R000030257 |
Scientific Title | A proSpective randomized Study comparing the effects of Empagliflozin versus sitagliptin on cardiac fat and function in patients with Type 2 diabetes (ASSET study) |
Date of disclosure of the study information | 2017/02/28 |
Last modified on | 2022/09/05 09:06:38 |
A proSpective randomized Study comparing the effects of Empagliflozin versus sitagliptin on cardiac fat and function in patients with Type 2 diabetes (ASSET study)
A proSpective randomized Study comparing the effects of Empagliflozin versus sitagliptin on cardiac fat and function in patients with Type 2 diabetes (ASSET study)
A proSpective randomized Study comparing the effects of Empagliflozin versus sitagliptin on cardiac fat and function in patients with Type 2 diabetes (ASSET study)
A proSpective randomized Study comparing the effects of Empagliflozin versus sitagliptin on cardiac fat and function in patients with Type 2 diabetes (ASSET study)
Japan |
Type 2 Diabetes Mellitus
Endocrinology and Metabolism |
Others
NO
To clinically evaluate the efficacy of a SGLT2 inhibitor (empagliflozin) compared to a DPP-4 inhibitor (sitagliptin) on the amount of ectopic fat accumulation with a special focus on pericardial fat, insulin resistance in tissues (heart, liver, muscle, and adipose tissues), and cardiac function among Japanese T2DM patients.
Efficacy
The changed amount and percent change from baseline of the following value are evaluated:
* Amount of pericardial fat
The changed amount and percent change from baseline of each value below are evaluated:
1. Myocardial intracellular fat amount
2. Cardiac function
3. Amount of fat accumulation in tissue (liver intracellular lipid content, intramyocellular and extramyocellular lipid contents)
4. Insulin sensitivity (in myocardium, liver, muscle, adipose tissue)
5. Myocardial fatty acid metabolism index (123I-BMIPP uptake (early/first-half image), 123I-BMIPP uptake (latter/second-half image), washout rate)
6. % suppression of EGP (suppression of hepatic glucose production rate)
7. Glucose infusion rate (GIR)
8. Glucose disappearance rate (Rd)
9. Insulin secretion index (C-peptide, plasma insulin, HOMA-beta)
10. Insulin resistance index (HOMA-IR)
11. Other insulin sensitivity index (D2Glucose, glucose level, FFA)
12. Blood glucagon
13. Energy metabolism index (calorimetric examination: amount of energy consumption, oxygen consumption and carbon dioxide emission)
14. Cardiac metabolism marker (renin activity, aldosterone, aldosterone/renin activity ratio, BNP, H-FABP)
15. Oxidation stress marker (urinary 8OHdG)
16. Inflammatory marker (hsCRP)
17. Adipose tissue hormone index (high-molecular weight adiponectin, leptin)
18. Other blood test item (quantitative albumin, HbA1c, blood glucose, TG, T-Cho, HDL, LDL, complete blood count, Na, K, Cl, uric acid, Amy, serum creatinine, eGFR, FFA, blood ketone body, AST, ALT, gamma-GTP, BUN, apolipoprotein)
19. Other urine test item (general urine test, microalbuminuria, urinary glucose, urinary ketone body, urinary Na, urinary K, urinary Cl, urinary creatinine, eGFR)
20. Body weight, blood pressure, heart rate, BMI, body composition (body fluid, bone mass, muscle mass, amount of fat, body fat percentage, basal metabolism quantity)
21. Chang in amount of meal consumed and the meal contents (BDHQ BOX)
22. Medication adherence rate (using medication adherence diary)
23. Occurrence rate of adverse events
Interventional
Parallel
Randomized
Individual
Open -but assessor(s) are blinded
Active
2
Treatment
Medicine |
Group A: Administer empagliflozin
Patients in the empagliflozin group take empagliflozin 10 mg once a day orally before or after breakfast for 12 weeks.
Group B: Administer sitagliptin
Patients begin with sitagliptin 50 mg a day, in principle, and increase the dose to 100 mg from their observation point of the 4th week, if it is possible. They also take sitagliptin orally once a day before or after breakfast for 12 weeks.
20 | years-old | <= |
75 | years-old | > |
Male and Female
Patients who meet all of the following criteria are included in this study:
1. At the time of giving consent, T2DM patients whose HbA1c (NGS) is out of the range set by the Treatment Guide for Diabetes 2016-2017, which is 6.0% or higher and below 10.0% even though patients have treated with 1) a dietary and exercise regimen, or 2) monotherapy of any alpha-glucosidase inhibitor, sulphonylurea*, or glinide-based medicine in addition to a dietary and exercise regimen, or 3) a combination therapy of any alpha-glucosidase inhibitor and sulphonylurea* medicine, or any alpha-glucosidase inhibitor and glinide-based medicine in addition to a dietary and exercise regimen
2. Male and female patients who are at age of 20 years or older and younger than 75 years when giving their consent
3. Patients with BMI 22 kg/m2 or greater
4. Patients who can give their consent in a written form
*Up to glimepiride 2 mg, glibenclamide 1.25 mg, and gliclazide 40 mg are considered as sulphonylurea treatment regimen
Patients who fall into any of the following criteria are excluded from participating in the study:
1. Type 1 diabetes mellitus or secondary diabetes
2. Patients with BMI below 22kg/m2
3. Moderate to severe renal function impairment or at the terminal stage of renal failure (eGFR below 45mL/min/1.73m2)
4. Patients who had stroke, cerebral infarction within 12 weeks before giving their consent
5. Patients with myocardial infarction or angina pectoris in the past, or with atrial fibrillation currently
6. Patient with LVEF below 30%
7. Patients with infectious disease
8. Patients with malignancy (However, those who have completed treatment and/or show no redevelopment of malignancy, as well as manifest some degree of remission can be considered to be participants of this study)
9. Patients with connective tissue disease (However, those T2DM patients who have treated with prednisolone 5mg or less and show stable conditions can be considered to be participants of this study)
10. Patients with hepatocirrhosis
11. Patients with viral or autoimmune, or drug-induced hepatitis
12. Patients who are alcoholic or excessive drinkers
13. Patients are currently pregnant, possibly pregnant, breast-feeding, or planning to be pregnant during the study
14. Patients have a medical history of hypersensitivity to the study drugs
15. If the study drugs are contradicted to use
16. Patients with Hb below 12g/dl
17. Patients with other conditions that the investigator/researcher thinks inappropriate for the study
44
1st name | |
Middle name | |
Last name | Professor Takahisa Hirose, Instructor Naoki Kumashiro |
Toho University Omori Medical Center
Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine
6-11-1 Omori-nishi, Ota-ku, Tokyo
03-3762-4151
ken.kanazawa@med.toho-u.ac.jp
1st name | |
Middle name | |
Last name | Hiroki Takayama |
Soiken Inc.
Clinical Study Support Division
NBF Ogawamachi Building 4F, 1-3-1 Ogawamachi, Kanda, Chiyoda-ku, Tokyo
03-3295-1350
takayama@soiken.com
the Japan Society for Patient Reported Outcome (PRO)
Nippon Boehringer Ingelheim Co., Ltd.
Profit organization
NO
2017 | Year | 02 | Month | 28 | Day |
Unpublished
Main results already published
2016 | Year | 12 | Month | 15 | Day |
2019 | Year | 10 | Month | 04 | Day |
2017 | Year | 03 | Month | 01 | Day |
2019 | Year | 06 | Month | 17 | Day |
2017 | Year | 02 | Month | 28 | Day |
2022 | Year | 09 | Month | 05 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030257
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |